The study investigated the safety and efficacy of a new conditioning regimen with cladribine before allogeneic stem cell transplantation in 16 children with relapsed or refractory acute myeloid leukemia.[1] All patients achieved successful hematopoietic reconstitution, with neutrophils restored in a median of 12 days and platelets in 15 days.[1] Serious adverse effects were rare - toxicity I. and II. Grade III occurred in 31.3% of patients, while no grade III toxicity was observed. or IV. degree.[1] Acute graft-versus-host disease occurred in 50% of patients and chronic in 26.7% of 15 evaluable patients.[1] Post-transplant infections occurred in 31.3% of patients, mostly viral.[1] One-year disease-free survival was 87.4% and the relapse rate was only 6.3%.[1] However, the authors emphasized that due to the small number of patients and the lack of a control group, larger studies are needed to confirm these favorable results.[1]